Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510313 | 0.89 | ALDH1A1 (0.33) | GLRA1SLC6A9OR51E2TSHRALDH1A1 | |
| SCHEMBL9243432 | 0.87 | CA12 (0.44) | LMNAHDAC3TSHRHDAC1HDAC2 | |
| SCHEMBL19833104 | 0.85 | ODC1 (0.32) | GABRR1LMNATHRBBLMKMT2A | |
| SCHEMBL3541127 | 0.84 | — | — | |
| SCHEMBL1162074 | 0.83 | CA12 (0.48) | LMNAHDAC3TSHRHDAC4HDAC1 | |
| SCHEMBL8000274 | 0.83 | GABRR3 (0.31) | GABRR1LMNATHRBBLMKMT2A | |
| SCHEMBL19925599 | 0.82 | LMNA (0.43) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Hydrochloric Acid SCHEMBL20641202 | 0.82 | LMNA (0.36) | LMNABLMKMT2ANPSR1MEN1 | |
| SCHEMBL27584046 | 0.82 | LMNA (0.36) | LMNAKMT2ACYP2D6MEN1ALDH1A1 | |
| SCHEMBL1028108 | 0.82 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117980327-A | Specific coupling of antibodies | 杭州多禧生物科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4352088-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794946-A | Long acting dual GIP/GLP-1 peptide conjugates and methods of use | 斯克利普斯研究所 | 2024-03-29 | — | — | CN | disclosed |
| EP-4168009-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | Hangzhou DAC Biotech Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115847665-A | Crushing process for recovering perfluoroether rubber and perfluoroether sealing element prepared by same | 上海芯密科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022257979-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022078524-A4 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | disclosed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115052886-A | GLP2 receptor agonists and methods of use | 斯克利普斯研究所 | 2022-09-13 | — | — | CN | disclosed |
| CN-115052615-A | Peptide conjugates and methods of use | 斯克利普斯研究所 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021212638-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-28 | — | — | WO | disclosed |
| EP-3897734-A1 | ADCS WITH THIOL MULTIPLEX LINKERS | Seagen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-107205961-B | Prodrugs of phenolic TRPV1 agonists | 同心镇痛药物公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020132655-A1 | ADCS WITH THIOL MULTIPLEX LINKERS | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2009060158-A1 | 4- (4-CYANOPHENYL) -1- (3-TRIFLUOROMETHYLPHENYL) -3,4, 6, 7-TETRAHYDRO-1H-PYRROLO [3, 4- D] PYRIMIDINE-2, 5-DIONE DERIVATIVES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
| WO-2004026846-A1 | DNA-TARGETED BENZOTRIAZINE 1,4-DIOXIDES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | HIF1AN, HIF1A, HYOU1 | GLRA1 948/4885SLC6A9 3556/4885OR51E2 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.